论文部分内容阅读
目的:探讨美沙拉嗪联合升脾法对溃疡性结肠炎疗效的影响。方法:选取2012年3月至2014年3月本院确诊的溃疡性结肠炎患者64例,依据随机分配原则分为拉嗪组和吡啶组,每组32例,所有患者均给予升脾法常规治疗,吡啶组患者在常规治疗基础上给予口服1 g柳氮磺吡啶治疗,拉嗪组患者在常规治疗基础上给予口服1 g美沙拉嗪治疗,统计分析两组患者治疗期间不良反应发生情况和治疗效果。结果:拉嗪组和吡啶组患者治疗期间不良反应发生率分别为12.50%、34.38%,组间比较,差异有统计学意义(P<0.05);拉嗪组和吡啶组患者治疗有效率分别为93.75%、71.87%,组间比较,差异有统计学意义(P<0.05)。结论:美沙拉嗪联合升脾法治疗可有效减少溃疡性结肠炎患者治疗期间不良反应的发生以及提高临床疗效,有利于加快患者治疗后身体的恢复。
Objective: To investigate the effect of mesalazine combined with spleen-lifting therapy on the curative effect of ulcerative colitis. Methods: Sixty-four patients with ulcerative colitis diagnosed in our hospital from March 2012 to March 2014 were randomly divided into two groups according to the principle of random distribution: 32 patients in each group, and all patients were given routine splenomegaly The patients in the pyridine group were treated with 1 g sulfasalazine orally on the basis of routine treatment. The patients in the group LAC were given orally 1 g mesalazine orally on the basis of conventional treatment. The incidences of adverse reactions in both groups were statistically analyzed and treatment effect. Results: The incidence of adverse reactions in the patients of the pyrazin group and the pyridine group was 12.50% and 34.38%, respectively, with significant difference between the two groups (P <0.05). The effective rates of the patients in the pyrazine group and the pyridine group were 93.75% and 71.87%, respectively. The differences between the two groups were statistically significant (P <0.05). Conclusion: The combination of mesalazine and spleen-lifting therapy can effectively reduce the incidence of adverse reactions and improve the clinical efficacy during the treatment of patients with ulcerative colitis, which will help to speed up the recovery of patients after treatment.